US Purchases $290 Million Worth of Anti-Radiation Medicine
With Russia remaining unrelenting in their threats to incite an atomic apocalypse as they falter in Ukraine, US officials don’t appear to be taking any chances.
Russian President Vladimir Putin has repeatedly suggested that those interfering with his plans in Ukraine would face his nuclear wrath, and his cronies in the state media have reiterated that possibility with a terrifying redundancy.
Now as two pieces of Moscow’s nuclear arsenal begin to travel from away from their normal stations, the US is stocking up on some emergency radiation treatment.
The US government has purchased a significant supply of radiation-injury drugs as the Russian president threatened the use of nuclear weapons.
A $290 million procurement of the drug Nplate, to treat acute radiation syndrome (ARS), was announced by the US Health and Human Services (HSS).
The government confirmed it was the first purchase of the drug, manufactured by the California pharmaceutical company Amgen.
Officials didn’t want ordinary Americans to be alarmed, however.
An HSS spokesman told The Telegraph: “This is part of our ongoing work for preparedness and radiological security. It has not been accelerated by the situation in Ukraine.”
It is understood the HSS has been working with Amgen, and similar companies, for some years.
The US has maintained a stockpile of Leukine, a drug which also treats ARS, since 2013.
Russia’s latest nuclear threats are “not a bluff” according to Putin, but global leaders have been a bit dismissive any way.